Trial Profile
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs I-131-Apamistamab (Primary) ; Asparaginase; Azacitidine; Carboplatin; Cladribine; Clofarabine; Cyclophosphamide; Cytarabine; Daunorubicin; Decitabine; Doxorubicin; Enasidenib; Etoposide; Fludarabine; Gemtuzumab ozogamicin; Gilteritinib; Idarubicin; Ivosidenib; Midostaurin; Mitoxantrone; Sorafenib; Tioguanine; Topotecan; Venetoclax
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms Iomab-B SIERRA; SIERRA; SIERRA in AML
- Sponsors Actinium Pharmaceuticals
- 26 Feb 2024 According to Actinium Pharmaceuticals media release, new analysis from this trial were presented at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT (American Society for Transplantation and Cellular Therapy and CIBMTR (Center for International Blood and Marrow Transplant Research).
- 26 Feb 2024 Results presented in an Actinium Pharmaceuticals media release.
- 23 Feb 2024 According to Actinium Pharmaceuticals media release, 131I-Apamistamab improves outcomes from this trial will be presented in oral presentations in upcoming at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT (American Society for Transplantation and Cellular Therapy and CIBMTR (Center for International Blood and Marrow Transplant Research) being held in San Antonio, Texas.